Key Points
- Director sale: Tempus AI Director David Epstein sold 370 shares on Feb. 2 at an average price of $59.41 for $21,981.70, reducing his holding by 1.4% to 26,051 shares (disclosed in an SEC Form 4).
- Operational and valuation snapshot: Shares opened at $54.43 and trade below the 50‑day ($67.31) and 200‑day ($73.92) averages, with a 12‑month range of $36.22–$104.32 and a $9.68B market cap; the company reported -$0.11 EPS (beat estimates) and $334.2M revenue (up 84.7% YoY) but remains unprofitable with negative margins and ROE.
- Institutional and analyst stance: Large holders like Vanguard increased positions (Vanguard now owns ~10.26M shares), while analyst coverage is mixed—six Buy, six Hold, one Sell—with a consensus target of $87.20 (MarketBeat average rated "Hold").
Tempus AI, Inc. (NASDAQ:TEM - Get Free Report) Director David Epstein sold 370 shares of the stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $59.41, for a total value of $21,981.70. Following the completion of the sale, the director owned 26,051 shares of the company's stock, valued at $1,547,689.91. The trade was a 1.40% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website.
Tempus AI Price Performance
NASDAQ:TEM opened at $54.43 on Thursday. The business's 50-day moving average is $67.31 and its 200 day moving average is $73.92. Tempus AI, Inc. has a 12 month low of $36.22 and a 12 month high of $104.32. The company has a market capitalization of $9.68 billion, a P/E ratio of -45.80 and a beta of 5.22. The company has a current ratio of 3.28, a quick ratio of 3.12 and a debt-to-equity ratio of 2.45.
Tempus AI (NASDAQ:TEM - Get Free Report) last released its quarterly earnings data on Tuesday, November 4th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.16) by $0.05. The business had revenue of $334.21 million for the quarter, compared to the consensus estimate of $328.89 million. Tempus AI had a negative return on equity of 73.21% and a negative net margin of 18.45%.The company's revenue was up 84.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.46) EPS. On average, equities research analysts forecast that Tempus AI, Inc. will post -6.15 earnings per share for the current fiscal year.
Institutional Trading of Tempus AI
Several large investors have recently added to or reduced their stakes in TEM. Vanguard Group Inc. raised its stake in shares of Tempus AI by 8.7% in the fourth quarter. Vanguard Group Inc. now owns 10,258,621 shares of the company's stock worth $605,772,000 after purchasing an additional 817,014 shares during the last quarter. GC Wealth Management RIA LLC acquired a new position in Tempus AI in the 4th quarter worth approximately $399,267,000. Sumitomo Mitsui Trust Group Inc. raised its position in Tempus AI by 1.2% during the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 3,504,823 shares of the company's stock worth $206,960,000 after buying an additional 41,728 shares during the last quarter. Voloridge Investment Management LLC boosted its holdings in shares of Tempus AI by 183.0% in the 3rd quarter. Voloridge Investment Management LLC now owns 1,607,083 shares of the company's stock valued at $129,708,000 after acquiring an additional 1,039,176 shares during the last quarter. Finally, Franklin Resources Inc. increased its stake in shares of Tempus AI by 0.4% in the third quarter. Franklin Resources Inc. now owns 1,456,120 shares of the company's stock worth $117,523,000 after acquiring an additional 5,375 shares during the period. Hedge funds and other institutional investors own 24.22% of the company's stock.
Analyst Upgrades and Downgrades
A number of analysts recently issued reports on TEM shares. Piper Sandler lowered their price target on Tempus AI from $105.00 to $80.00 and set a "neutral" rating for the company in a report on Tuesday, November 11th. Morgan Stanley increased their price target on Tempus AI from $80.00 to $85.00 and gave the stock an "overweight" rating in a research report on Monday, December 1st. Needham & Company LLC lifted their price objective on Tempus AI from $70.00 to $100.00 and gave the company a "buy" rating in a report on Wednesday, November 5th. Canaccord Genuity Group dropped their target price on shares of Tempus AI from $95.00 to $80.00 and set a "buy" rating on the stock in a report on Monday, December 22nd. Finally, JPMorgan Chase & Co. reduced their price target on shares of Tempus AI from $85.00 to $80.00 and set a "neutral" rating for the company in a report on Monday, December 15th. Six equities research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Hold" and a consensus target price of $87.20.
Read Our Latest Report on Tempus AI
About Tempus AI
(
Get Free Report)
Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.
The company's core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
